The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1221
Omega-3 Polyunsaturated Fatty Acids (Omacor) for Hypertriglyceridemia
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Omega-3 Polyunsaturated Fatty Acids (Omacor) for Hypertriglyceridemia
A highly concentrated omega-3 polyunsaturated fatty acid (PUFA) preparation (Omacor - Reliant) has been approved by the FDA as an adjunct to diet for treatment of very high plasma triglyceride concentrations (>=500 mg/dL). Omacor is a combination of...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Omega-3 Polyunsaturated Fatty Acids (Omacor) for Hypertriglyceridemia
Article code: 1221b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.